Angiogenesis in myelodysplastic syndromes

Abstract

It is now well established that solid tumour growth depends on angiogenesis. However, less is known about the generation of new vessels in haematological malignancies and, in particular, in preleukaemic-myelodysplastic syndromes (MDS). In this study, bone marrow microvessel density (MVD) was assessed by immunohistochemistry and compared in trephine biopsies from 14 controls, five infectious disease (ID), 82 MDS, 15 acute myeloid leukaemia (AML) and 14 myeloproliferative disorder (MPD) patients. Statistical analysis (P < 0.001) demonstrated that MDS MVD was higher than in controls and ID (21 +/- 9 vs 6 +/- 2 and 10 +/- 8 respectively) but lower than AML (30 +/- 12) and MPD (40 +/- 12). Among MDS-FAB subtypes, MVD was significantly higher in RAEB-t, CMML and fibrosis subsets compared to RA, RARS and RAEB subsets (P= 0.008). To further investigate angiogenesis machinery, the expression of vascular endothelial growth factor (VEGF) was evaluated by means of immunohistochemistry in control, MDS, AML and MPD biopsies. Even though VEGF mRNA expression was reported in the past in AML cell cultures and cell lines, in our samples VEGF expression was found to be particularly strong in most of the megakaryocytes but significantly less prominent in other cell populations including blasts. Since our findings suggest a correlation between angiogenesis and progression to leukaemia, additional work is now warranted to determine what regulates the generation of new vessels in MDS and leukaemia.

References 21

1. 1.

   Aceñero M. J., González J. F., Gallego M. G., Ballesteros P. A. Vascular enumeration as a significant prognosticator for invasive breast carcinoma. J Clin Oncol. 1998;16(5):1684-1688.

   Not in our library10.1200/jco.1998.16.5.1684

2. 2.
   Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology · 1998

   No notice
3. 3.

   Boehm T., Folkman J., Browder T., O'Reilly M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390(6658):404-407.

   Not in our library10.1038/37126

4. 4.

   Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18(1):4-25.

   Not in our library10.1210/edrv.18.1.0287

5. 5.

   Fiedler W., Graeven U., Ergün S., Verago S., Kilic N., Stockschläder M., Hossfeld D. K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89(6):1870-1875.

   Not in our library

6. 6.

   Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.

   Not in our library10.1038/nm0195-27

7. 7.

   Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6.

   Not in our library10.1093/jnci/82.1.4

8. 8.

   Foss H. D., Araujo I., Demel G., Klotzbach H., Hummel M., Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 1997;183(1):44-50.

   Not in our library10.1002/(sici)1096-9896(199709)183:1<44::aid-path1103>3.0.co;2-i

9. 9.

   Fukumura D., Xavier R., Sugiura T., Chen Y., Park E. C., Lu N., Selig M., Nielsen G., Taksir T., Jain R. K. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94(6):715-725.

   Not in our library10.1016/s0092-8674(00)81731-6

10. 10.

    Gimbrone M. A., Leapman S. B., Cotran R. S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972;136(2):261-276.

    Not in our library10.1084/jem.136.2.261

11. 11.

    Graham C. H., Rivers J., Kerbel R. S., Stankiewicz K. S., White W. L. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol. 1994;145(3):510-514.

    Not in our library

12. 12.

    Greenberg P., Cox C., LeBeau M. M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.

    Not in our library

13. 13.

    Lewis C. E., Leek R., Harris A., McGee J. O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol. 1995;57(5):747-751.

    Not in our library10.1002/jlb.57.5.747

14. 14.

    Linderholm B., Tavelin B., Grankvist K., Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol. 1998;16(9):3121-3128.

    Not in our library10.1200/jco.1998.16.9.3121

15. 15.

    Möhle R., Green D., Moore M. A., Nachman R. L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94(2):663-668.

    Not in our library10.1073/pnas.94.2.663

16. 16.

    Nguyen M., Watanabe H., Budson A. E., Richie J. P., Hayes D. F., Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86(5):356-361.

    Not in our library10.1093/jnci/86.5.356

17. 17.

    Perez-Atayde A. R., Sallan S. E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815-821.

    Not in our library

18. 18.

    Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90(8):3167-3172.

    Not in our library

19. 19.

    Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87(3):503-508.

    Not in our library10.1111/j.1365-2141.1994.tb08304.x

20. 20.

    Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.

    Not in our library10.1056/nejm199101033240101

21. 21.

    Yamaguchi H., Ishii E., Saito S., Tashiro K., Fujita I., Yoshidomi S., Ohtubo M., Akazawa K., Miyazaki S. Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Br J Haematol. 1996;94(4):606-611.

    Not in our library10.1046/j.1365-2141.1996.d01-1855.x

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.